Australia's most trusted
source of pharma news
Thursday, 23 July 2026
Posted 23 July 2026 AM
GSK is launching a large-scale, placebo-controlled, blind study to assess whether its shingles vaccine Shingrix can prevent dementia.
The study will evaluate 33,600 adults aged 76 and older in Finland, with participants randomised in a 3:1 ratio to receive either the vaccine or placebo.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.